Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome

RC Grenn, S Yalavarthi, AA Gandhi… - Annals of the …, 2017 - ard.bmj.com
RC Grenn, S Yalavarthi, AA Gandhi, NM Kazzaz, C Núñez-Álvarez, D Hernández-Ramírez…
Annals of the rheumatic diseases, 2017ard.bmj.com
Objectives Patients with antiphospholipid syndrome (APS) are at risk for subclinical
endothelial injury, as well as accelerated atherosclerosis. In the related disease systemic
lupus erythematosus, there is a well-established defect in circulating endothelial
progenitors, which leads to an accrual of endothelial damage over time. This defect has
been at least partially attributed to exaggerated expression of type I interferons (IFNs). We
sought to determine whether these pathways are important in APS. Methods We studied 68 …
Objectives
Patients with antiphospholipid syndrome (APS) are at risk for subclinical endothelial injury, as well as accelerated atherosclerosis. In the related disease systemic lupus erythematosus, there is a well-established defect in circulating endothelial progenitors, which leads to an accrual of endothelial damage over time. This defect has been at least partially attributed to exaggerated expression of type I interferons (IFNs). We sought to determine whether these pathways are important in APS.
Methods
We studied 68 patients with primary APS. Endothelial progenitors were assessed by flow cytometry and functional assay. Type I IFN activity was determined by a well-accepted bioassay, while peripheral blood mononuclear cells were scored for expression of IFN-responsive genes.
Results
Endothelial progenitors from patients with APS demonstrated a marked defect in the ability to differentiate into endothelial cells, a phenotype which could be mimicked by treating control progenitors with APS sera. Elevated type I IFN activity was detected in the circulation of patients with APS (a finding that was then replicated in an independent cohort). While IgG depletion from APS sera did not rescue endothelial progenitor function, the dysfunction was successfully reversed by a type I IFN receptor-neutralising antibody.
Conclusions
We describe, for the first time to our knowledge, an IFN signature in primary APS and show that this promotes impaired endothelial progenitor function. This work opens the door to novel approaches that may mitigate vascular damage in APS, such as anti-IFN drugs.
ard.bmj.com